(n=6) remain disease-free more than two years after treatment 80% of patients treated with SYNC-T Therapy SV-102 (n=15) alive ...

A new alpha-emitting radiopharmaceutical therapy (RPT) for advanced prostate cancer was well tolerated, with no dose-limiting ...

The FDA has expanded its approval of talazoparib in combination with enzalutamide to include men with metastatic androgen ...

Oct 24 (Reuters) - Johnson & Johnson on Saturday said its experimental once-daily oral prostate cancer drug caused tumors to ...

Johnson & Johnson (J&J) said that an early-stage trial of JNJ-6143 (previously HLD-0915) found that the novel oral Regulated ...

A new alpha-emitting radiopharmaceutical therapy (RPT) for advanced prostate cancer was well tolerated, with no dose-limiting ...

Adding darolutamide to ADT and RT improved metastasis-free survival, but questions persist ...

Prostate cancer can be a serious disease, but most men diagnosed with prostate cancer do not die from it. In fact, more than 3.5 million men in the United States who have been diagnosed with prostate ...

Pfizer’s Talzenna is now the first PARP inhibitor approved by the FDA to treat men with metastatic hormone-sensitive prostate ...

Johnson & Johnson (NYSE:JNJ) has presented Phase 1 clinical trial results for JNJ-6143, an investigational oral treatment for advanced prostate cancer, at the European Society for Medical Oncology ...

A crowd of South African men ran through the streets of Johannesburg in purple swim briefs to raise awareness about prostate ...

An updated clinical guideline from the American Society for Radiation Oncology (ASTRO) provides evidence-based ...